1-Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19 (3): 271-285.

2-Trinchet JC, Beaugrand M. Augmentation de l’incidence du carcinome hépatocellulaire dans les pays occidentaux. Gastroenterol Clin Biol 1999; 23: 1286-1288

3-Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1974-94. Lancet 1997; 350: 1142-1143.

4-Deuffic S, Poynard T. Trends in primary liver cancer. Lancet 1998; 351: 214-215.

5-El-Serag HB. Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999; 340: 745-750.

6-Okuda K. Hepatocellular carcinoma. J Hepathol 2000;32 (suppl.1): 225-237.

7-EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepathol 1999; 30: 956-961.

8-Deuffic S, Buffat L, Poynard T, Valleron AJ. Modelling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-1601.

9-Suarez Y, Sala M, Llovet JM, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 1999; LXII: 410-414.

10-Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000; 76: 4-11.

11-Bronowiki JP, Vetter D, Dumas F, Boudjema K, Bader R, Weiss AM, Venger JJ, Boissel P, Bigard AM, Doffel M. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74: 16-24.

12-Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G, Gasbarrini G. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995. 75: 2427-2434.

13-Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184.

14-Groupe d’étude et de traitement du carcinome hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. New Engl J Med 1995; 332: 1256-1261.

15-Nakakuma K, Tashiro, S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985; 154: 15-17.

16-Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, Konno T, Iwamoto S, Ohnishi K, Okuda K. Hepatocellular carcinoma detected by iodized oil. Radiology 1998; 154: 19-24.

17-Miller DL, O’Leary TJ, Girton M. Distribution of iodized oil within the liver after hepatic arterial injection. Radiology 1987; 162: 849-852.

18-Park C, Choi SI, Kim H, Yoo HS, Lee YB. Distribution of Lipiodol in hepatocellular carcinoma. Liver 1990; 10: 72-78.

19-Chou FI, Fang KC, Chung C, Lui WY, Chi CW, Liu RS, Chan WK. Lipiodol uptake and retension by human hepatoma cells. Nucl Med Biol 1995; 22 (3): 379-386.

20-Park CH, Suh JH, Yoo HS, Lee JT, Kim DI. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Therapeutic feasibility study. Clin Nucl Med 1986; 11: 514-517.

21-Raoul JL, Duvauferrier R, Bourguet P, Bretagne JF, Coornaert S, Darnault P, Deugnier M, Herry JY, Gastard J. L’angiographie lipiodolée au cours des carcinomes hépatocellulaires. Apport du Lipiodol marqué à l’iode 131. J Radiol 1986; 67: 797-801.

22-Raoul JL, Bourguet P, Bretagne JF, Duvauferrier R, Coornaert S, Darnault P, Ramée A, Herry JY, Gastard J. Hepatic artery injection of I-131-labeled Lipiodol. Part 1. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 541-545.

23-Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, Uchiyama N, Sonoda T, Shinohara S. Biodistribution and in vivo kinetics of iodine 131 Lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988; 29: 1066-1077.

24-Hind RE, Loizidou M, Perring S, Fleming J, Batty V, Birch S, Taylor I. Biodistribution of Lipiodol following hepatic arterial injection. Br J Surg 1992; 79: 952-954.

25-Raoul JL, Duvauferrier R, Bretagne JF, Bourguet P, Bekhechi D, Deugnier M, Siproudhis L, Gosselin M. Usefulness of hepatic artery injection of iodized oil and I-131-labeled iodized oil before the therapeutic decision in hepatocellular carcinoma. J Scan Gastroenterol 1993; 28: 217-223.

26-Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985; 56 (4): 751-757.

27-Risse JH, Grünvald F, Kersjes W, Strunk H, Caselman WH, Palmedo H, Bender H, Biersack HJ. Intra-arterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 2000; 15: 65-71.

28-Toubeau M, Touzery C, Berriodo-Riedinger A, Cochet A, Brunotte F. 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma. Eur J Nucl Med 2001; 28: 669-670.

29-Kobayashi H, Hidaka H, Kajiya Y, Tanoue P, Inoue H, Ikeda K, Nakajo M, Shinohara S. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diag 1986; 27: 139-147.

30-Park CH, Suh JH, Yoo HS, Lee JT, Kim DI, Kim BS. Treatment of hepatocellular carcinoma (HCC) with radiolabelled Lipiodol: a preliminary report. Nucl Med Comm 1987; 8: 1075-1087.

31-Bretagne JF, Raoul JL, Bourguet P, Duvauferrier R, Deugnier Y, Faroux R, Ramée A, Herry JY, Gastard J. Hepatic artery injection of I-131-labeled Lipiodol. Radiology 1988; 168: 547-550.

32-Yoo HS, Park CH, Suh JH, Lee JT, Kim DI, Kim BS, Madsen MT. Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. Cancer Chemother Pharmacol 1989; 23 (suppl): S54-S58.

33-Lui WY, Liu RS, Chiang JH, Lo JG, Lai KH, King KL, Cheng HC, Wei YY, Chi CW, P’eng FK, Chan WK. Report of a pilot study of intra-arterial injection of I-131 Lipiodol for the treatment of hepatoma. Chin Med J (Taipei) 1990; 46: 125-133.

34-Yoo HS, Lee JT, Kim KW, Kim BS, Choi HJ, Lee KS, Park CI, Park CY, Suh JH, Loh JK. Nodular hepatocellular carcinoma. Treatment with subsegmental intra-arterial injection of iodine 131-labeled iodized oil. Cancer 1991; 68: 1878-1884.

35-Raoul JL, Bretagne JF, Caucanas JP, Pariente EA, Boyer J, Paris JC, Michel H, Bourguet P, Victor G, Therain F, Lejeune JJ, Lemaire B, Collet H, Duvauferrier R, Puech JL, Viala JF, L’Hoste P, Poisonnier M, Guiry P. Internal radiation Therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 1992; 69: 346-352.

36-Yumoto Y, Jinno K, Inatsuki S, Moriwaki S, Hanafusa T, Yumoto E, Shiota T, Higashi T, Koide N, Hada H, Murase K, Hamamoto K, Tsuji T. Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother Pharmacol 1992; 31 (suppl): S128-S136.

37-Kajiya Y, Kobayashi H, Nakajo M. Transarterial internal radiation therapy with I-131 lipiodol for multifocal hepatocellular carcinoma: intermediate and long term results. Cardiovasc Intervent radiol 1993; 16: 150-157.

38-Leung WT, Lau WY, Ho S, Chan M, Leung N, Lin J, Ho KC, Metreweli C, Johnson PJ, Li AKC. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35: 1313-1318.

39-Yoo HS, Park CH, Lee JT, Kim KW, Yoon CS, Suh JH, Park CY, Kim BS, Choi HJ, Lee KS, Park CI. Small hepatocellular carcinoma: high dose internal radiation therapy with super selective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 1994; 33 (suppl): S128-S133.

40-Bhattacharya S, Novel JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-Lipiodol chemotherapy versus 131Iodine –lipiodol Radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76: 2202-2210.

41-Maini CL, Scelsa MG, Fiumara C, Tofany A, Sciuto R, Tipaldi L, D’Annibale M, Santoro E. Superselective intra-arterial radiometabolic therapy with I-131 Lipiodol in hepatocellular carcinoma. Clin Nucl Med 1996; 21: 221-226.

42-De Baere T, Taourel P, Tubiana JM, Kuoch V, Ducreux M, Lumbroso J, Roche AJ. Hepatic intra-arterial 131 I iodized oil for treatment of hepatocellular carcinoma in patient with impeded portal venous flow. Radiology 1999; 212: 665-668.

43-Partensky C, Sassolas G, Henry L, Paliar P, Maddern GJ. Intra-arterial iodine 131-labeled Lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 2000; 135: 1298-1300.

44-Brans B, De Winter F, Defreyne L, Troisi R, Vanlangenhove P, Van Vlierberghe H, Lambert B, Praet M, de Hemptinne B, Dierckx RA. The anti-tumoral activity of neoadjuvant intra-arterial 131I-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 4: 333-338.

45-Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, Deunier YM, Gosselin M. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 1782-1787.

46-Preketes AP, Boyd S, Cooper D, McKay E, Smart RC, Qulnn R, Ross WB, Clingan P, Mc Call JL, Buttler SP, Glenn D, Clark E, Morris DL. Pulmonary toxicity following Lipiodol I-131 treatment for liver tumours. Reg Cancer Treat 1996; 9: 21-26.

47-Risse JH, Ponath C, Palmedo H, Menzel C, Grünwald F, Biersack HJ. Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver cancer. Eur J Nucl Med 2001; 28: 914-918.

48-Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, Bekhechi D, Deunier YM, Gosselin M. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 1156-1161.

49-Lau WY, Leung TWT, Ho SKW, Chan M, Machin D, Lau J, Chan ATC, Yeo W, Mok TSK, Yu SCH, Leung NWY, Johnson PJ. Adjuvant intra-arterial iodine-131-labelled Lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353: 797-801.

50-Ho S, Lau WY, Leung TWT, Johnson PJ. Internal radiation therapy for patients with primary or metastatic hepatic cancer. Cancer 1998; 83: 1894-1907.

51-Ho S, Lau WY Leung TWT, Chan M, Ngar YK, Johnson PJ, Li AKC. Partition model for estimating radiation doses from yttrim-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996; 23: 947-952.

52-Ho S, Lau WY Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimating radiation doses from yttrim-90 microspheres in the treatment of hepatic cancers. Eur J Nucl Med 1997; 24: 293-298.

53-Houle S, Yip TCK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, Cawthorn RH, Richemend-Cox K. Hepatocellular carcinoma: a pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172: 857-860.

54-Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70: 2250-2254.

55-Yan ZP, Lin G, Zhao HY, Dong YH. An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer. Cancer 1993; 72: 3210-3215.

56-Lau WY, Leung WT, Ho S, Leung NWY, Chan M, Lin J, Metreweli C, Johnson P, Li AKC. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70: 994-999.

57-Lau WY, Ho S, Leung TWT, Ho S, Chan M, Johnson P, Li AKC. Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intra-arterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40 (3): 583-592.

58-Cao X, He N, Sun J, Tan J, Zhang C, Yang J, Lu T, Li J. Hepatic radioembolisation with yttrium-90 glass microspheres for treatment of primary liver cancer. Chinese Medical Journal 1999; 112 (5): 430-432.

59-Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE. Treatment of non-resectable hepatocellular carcinoma with intrahepatic 90yttrium microspheres. J Nucl Med 2000; 41: 1673-1681.

60-Ho S, Lau JWY, Leung TWT. Intrahepatic 90Y-microspheres for hepatocellular carcinoma. Eur J Nucl Med 2001; 42: 1587-1589.

61-Jeong JM, Kim YJ, Lee YS, Ko JI, Son M, Lee DS, Chung JK, Park JH, Lee MC. Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001; 28: 197-204.